Power POCT, employee market price to buy back the company's old shares! Where does confidence in Smart come from?

Guide: A lifetime in the field of automobile manufacturing, turned around the hands of the birth of a successful medical device companySmart is a company dedicated to POCT (instant inspection), the company's products are exported to more than 80 countries and regions overseasIts animal POCT products account for nearly half of the domestic market shareNow, they have officially stepped into the field of medical POCT for human use and see new opportunities to take offit's hard to imagine anyone in their job, after 17 years in the field, someone else can step into a whole new field, and it's effectiveFor Ran Peng, everything today seems to be the result of chanceBut in the process there is frustration, there is persistence, there is blood, finally have today's first taste of success of the joythe beginning of the story as you would experienceAfter graduating from Wuhan Institute of Technology in automobile manufacturing, Ran Peng stepped into Chongqing Kafu Automotive Parts Co., Ltdas a professional counterpartEven after changing the company, he chose Zhejiang Wan'an Group, the backbone of auto parts manufacturingI've been in this industry for 17 yearsPerhaps he never thought that 17 years later, he would step out of the automotive industry positioned as a lifelong career, with medical devices, not to mention in his hands will be born in the POCT biochemical analysis industry in the dominant position of the instant inspection company - Chengdu Smart Technology Co., Ltdtwo people's studiofor Ran Peng, everything started with helping a friendIn 2005, for some reason a friend abroad, the name of a medical device company in Shenzhen entrusted to him managementIt is in this company, Ran Peng first came into contact with medical devices, and from then on with the development, production and sales of medical devices familiar with the medical device industry, he led the formation of a new product line, into the field of IVD (in vitro diagnostics) and semi-automatic biochemical analyzeras At that time, the domestic primary health care basic ally use semi-automatic biochemical analyzers, a single province of the market, tender procurement volume may be as high as thousands But after being exposed to ABAXIS's fully automatic biochemical analyzer, he discovered the advantages: small equipment, low blood collection, easy to operate, no professionals to operate This made him aware of the opportunities For more than a decade, he devoted almost all his efforts to the development of this product ABAXIS's POCT fully automatic biochemical analyzer is part of the NASA program and it's not easy to get through it After two years of research and development, several technical difficulties are still being erected there like a wall, leaving them powerless Although regret, but in the end can only choose to give up In 2009, after coming out of a friend's company, Ran Peng made a living from medical device sales, while continuing to figure out how to start all over again He has always been deeply concerned about the project that he was forced to give up In the end, he chose to approach the target in a different way - working with a leading university professor with decades of theoretical modeling and research experience to form a portable, fully automated biochemical analyzer pre-research studio, the technical secret behind the dead product as you continue to model, proof, verify.. Failure son-in-one, repeat time after time Those high walls of technology were disintegrated by them one by one Subsequently, hardware engineers, software engineers have joined the team Finally, in the light of hope, they set up Chengdu Smart Technology Co., Ltd., a company dedicated to POCT product research and applications, in August 2012 After the establishment of the company, began a comprehensive instrument, reagent, process research and development, but to the actual land sales, and four years have passed It wasn't until 2016 that the product was finally on sale After being widely accepted by users, Ran Peng was relieved 's first thoughts
even today, some in the industry see Smart as a company that has transitioned from an animal healthcare market to a human healthcare market The fact is that the company was founded to enter the medical care market for human use But given that human-use medical products need to involve clinical trials and documents before they go on sale, the process is long In order to survive, Smart pioneered the animal medicine market Who knows this mindless move, the achievement of Smart today in the field of animal medicine on the domestic biochemical analyzer on the strong position Through more than 3 years of deep cultivation and expansion of the domestic animal medical market, Smart has gained a solid market position, currently occupies more than 40% of the domestic animal medical market share Mr Ran expects to achieve 50% market coverage by 2020 Smart's SMT-120V fully automatic veterinary biochemical analyzer for the animal medical market, which combines conventional biochemical, clotting, electrolyte and partial immunization programs The instrument is very simple to operate, even if there is no professional training personnel, you can by adding samples, put into the reagent disk two simple steps, plus 11 minutes of waiting time, to obtain a complete and accurate test report Even the production of animal medical products, Mr Smart said, is manufactured in a GMP environment that meets medical requirements for human use SmartPOCT automatic biochemical analysis system uses constant light source detection technology, greatly reduces product cost, reduce stakes in measurement errors, the optimization of the reagent disk design, so that a single detection project up to more than 20, at the same time, the use of cloud technology and Internet and medical and other cutting-edge technology, can help operators remoteand accurate judgment of results Built-in centrifuges, automatic scanning and real-time quality control, with online troubleshooting, on-line monitoring instruments, to solve the problem of primary health care worries , although It wasn't until June this year that Smart's domestic registration certificate for instruments and a variety of consumables was included in the bag, but as early as July 2019, after taking part of the qualification documents, Smart began to lay out the human health care market After 10 years of accumulation, Ran Peng firmly believes that Smart in the human medical market will also be as strong as bamboo, 2020 sales revenue of medical products is expected to exceed 15 million yuan In Smart's expectation, in 2021, the sales revenue from human-use will exceed animal medicine, officially returning to the "people-oriented" development line in order to work hard in the market segment, Smart decided to focus on two product platforms over the next five years, one for the POCT fully automated biochemical analysis system and the other for the POCT chemical luminous immunoassay system In Ran Peng's expectation, immunization products will exceed the scale of sales of biochemical products in 2023 Using a single-product explosive strategy, Smart believes that the human healthcare market can be brilliant again rigorous, down-to-earth research basis and strict GMP production management norms, so that Smart's POCT fully automatic biochemical analysis system by domestic and foreign customers love At present, products are exported to more than 80 countries and regions around the world, of which 60% of the sales share in Europe and the United States Mr Ran has made no secret of Mr Smart's goal of being a global benchmark for cost-effectiveness Perhaps it is precisely because of such a bottom, the internal mood is high, full of energy In Ran Peng's words, there is an "event worthy of the history of the company's development", recently, the company by more than 40 key employees in partnership to pay 5.4 million, at the market price to buy back 2.4% of the old shares This is also a footnote for the company's future the future can be employees to buy back old shares, and the company's operating conditions, development prospects are inseparable From a two-person pocket team in 2010 to eight when it was founded in 2012, to a company with more than 210 people today, it's not just the number of people that's changing In 2016, the company officially sold the market for the veterinary market fully automatic biochemical analyzers, it took 6.7 million yuan in sales In 2017, 11 million; in 2018, 26 million; and in 2019, 45 million In 2020, the original plan sales reached 81 million, affected by the international outbreak, there may be about 20 million difference, but with the second half of 2019 human medical market cut-in, as well as the upcoming release of immune POCT products, new growth points continue to emerge, the company's future development is possible because of the special nature of the product, smart's current profit is more from instrument sales, but with the growth of the instrument market, its future earnings will rely more on service and consumables sales growth 's early focus on Smart comes from peers As early as March 2014, Smart completed the Angels' $10.4 million financing The round of financing Nanjing Plan Medical Equipment Co., Ltd and its partnership investment institutions led the investment, other executives personally with the investment In May 2018, Smart completed another Round A financing of $25 million, led by Sanno Biosensors Co., Ltd Smart's market valuation is more than $225 million, according to the latest round of equity deals has a very clear understanding of the market He believes that the POCT market is currently no shortage of speculation On the one hand, the endless new products, many new companies lack innovative and practical value, on the other hand, the public hospital inspection is still the exclusive control of the inspection department, has not yet liberalized the other departments of POCT equipment acceptance In addition, most Of the POCT products also lack the applicable industry standards, many are the use of large laboratory equipment standards, some indicators are inevitably far-fetched These are the real problems in the current hot POCT market faced with a situation in the industry, Smart says the only thing you can do is to keep his products more competitive For the future of planning, Mr Ran said it would hit the IPO in two or three years and complete a share-based restructuring this year At the same time, he firmly believes that next year, after the overall improvement of the international epidemic, whether sales performance or new product launches can make a new breakthrough At the same time, Smart will begin preparations for the next round of financing, laying the groundwork for a new take-off